RxDoctor Payments Data

Marthe-Sophie Lagueux, MD

Family Medicine · Mount Juliet, TNNPI 1457330649

Payments from drug & device makers

$13,264in general payments, 2019–2025

Across 767 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • GSK$2K
  • AbbVie$2K
  • Amgen$952
  • AstraZeneca$935
  • Lilly USA, LLC$819
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$13,14499%
  • Education$1201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,264 in reported general payments places this provider in the 95th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$154,657
Medicare patients
271
Services billed
3,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide112$152,726
MounjaroTirzepatide101$119,044
JanuviaSitagliptin Phosphate91$96,662
TrulicityDulaglutide83$88,238
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$67,792
JardianceEmpagliflozin66$66,435
MyrbetriqMirabegron53$46,303
EliquisApixaban33$37,071
RybelsusSemaglutide18$34,058
XareltoRivaroxaban42$30,054
FarxigaDapagliflozin Propanediol33$29,316
VascepaIcosapent Ethyl26$17,947
Spiriva RespimatTiotropium Bromide22$15,730
LinzessLinaclotide12$13,002
TradjentaLinagliptin14$11,880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$819$207,282184 claims
Novo NordiskOzempic, Rybelsus$3,042$186,784130 claims
MerckJanuvia$114$96,66291 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$540$94,045102 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,919$76,16886 claims
Astellas Pharma US IncMyrbetriq$372$46,30353 claims
PfizerEliquis$503$37,07133 claims
Johnson & JohnsonXarelto$241$30,05442 claims
AstraZenecaFarxiga$935$29,31633 claims
AbbVieLinzess, Synthroid$1,673$17,577133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Mount Juliet

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →